ANDA 74537, held by G & W Laboratories. Selegiline Hydrochloride.
As of Nov 21, 2026, ANDA 74537 (Selegiline Hydrochloride), held by G & W Laboratories, was first approved by FDA on Aug 2, 1996, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 2, 1996 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Selegiline Hydrochloride5MG · tablet;oral | Selegiline Hydrochloride | Discontinued |
| Apr 23, 1999 | Supplement 3Manufacturing | Approved | None posted |
| Jun 9, 1998 | Supplement 2Labeling | Approved | None posted |
| Jun 10, 1997 | Supplement 1Labeling | Approved | None posted |
| Aug 2, 1996 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters